Human CD44/CDW44/CSPG8 ORF/cDNA clone-Mammalian (Non-Viral Vector) plasmid (NM_000610)
Cat. No.: pGMPC004852
Size: 10 µg
Concentration: generally 0.5ug/ul, usually not less than 0.3ug/ul
Leading Time: 3-7 working days
Pre-made Human CD44/CDW44/CSPG8 Non-Viral expression plasmid (overexpression vector) for mouse CD44 overexpression in unique cell transient transfection and stable cell line development.
Go to
CD44/CDW44 products
collection>>
(antibodies,
antigen, VLP, mRNA, ORF viral vector, etc)
Product Description
Catalog ID | pGMPC004852 |
Gene Name | CD44 |
Accession Number | NM_000610 |
Gene ID | 960 |
Species | Human |
Product Type | Mammalian (Non-Viral Vector) plasmid (overexpression) |
Insert Length | 2229 bp |
Gene Alias | CDW44,CSPG8,ECM-III,ECMR-III,H-CAM,HCELL,Hermes-1,HUTCH-1,HUTCH-I,IN,LHR,MC56,MDU2,MDU3,MIC4,Pgp1 |
Fluorescent Reporter | EGFP |
Mammalian Cell Selection | Null |
Fusion Tag | 3xflag (C-Terminal) |
Promoter | CMV |
Resistance | Amplicin |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
---|---|---|
Biosimilar | GMP-Bios-INN-763 | Pre-Made Bivatuzumab Biosimilar, Whole Mab, Anti-Cd44 Antibody: Anti-CDW44/CSPG8/ECMR-III/HCELL/HUTCH-I/IN/LHR/MC56/MDU2/MDU3/MIC4/Pgp1 therapeutic antibody |
Target Antibody | GM-Tg-g-T78319-Ab | Anti-CD44/ CDW44/ CSPG8 monoclonal antibody |
Target Antigen | GM-Tg-g-T78319-Ag | CD44 VLP (virus-like particle) |
ORF Viral Vector | pGMLP002663 | Human CD44 Lentivirus plasmid |
ORF Viral Vector | pGMLV001274 | Human CD44 Lentivirus plasmid |
ORF Viral Vector | pGMPC004852 | Human CD44 Mammalian (Non-Viral Vector) plasmid |
ORF Viral Vector | vGMLP002663 | Human CD44 Lentivirus particle |
ORF Viral Vector | vGMLV001274 | Human CD44 Lentivirus particle |
Target information
Target ID | GM-T78319 |
Target Name | CD44 |
Gene ID | 960, 12505, 717204, 25406, 101098744, 403939, 281057, 100034221 |
Gene Symbol and Synonyms | CD44,CD44A,CDW44,CSPG8,ECM-III,ECMR-III,H-CAM,HCELL,HERMES,Hermes-1,HUTCH-1,HUTCH-I,IN,LHR,Ly-24,MC56,MDU2,MDU3,METAA,MIC4,Pgp-1,Pgp1,RHAMM |
Uniprot Accession | P16070 |
Uniprot Entry Name | CD44_HUMAN |
Protein Sub-location | Transmembrane Protein |
Category | Therapeutics Target, Immuno-oncology Target, INN Index |
Disease | colon cancer, Malignant neoplasm of bladder, Congenital occlusion of ureteropelvic junction, IgA glomerulonephritis, Lung cancer |
Gene Ensembl | ENSG00000026508 |
Target Classification | Checkpoint-Immuno Oncology |
The protein encoded by this gene is a cell-surface glycoprotein involved in cell-cell interactions, cell adhesion and migration. It is a receptor for hyaluronic acid (HA) and can also interact with other ligands, such as osteopontin, collagens, and matrix metalloproteinases (MMPs). This protein participates in a wide variety of cellular functions including lymphocyte activation, recirculation and homing, hematopoiesis, and tumor metastasis. Transcripts for this gene undergo complex alternative splicing that results in many functionally distinct isoforms, however, the full length nature of some of these variants has not been determined. Alternative splicing is the basis for the structural and functional diversity of this protein, and may be related to tumor metastasis. [provided by RefSeq, Jul 2008]
About GMVC
GMVC (GM Vector Core) is GeneMedi’s unique platform for QbD Viral vectors Processes development and manufacturing. In GMVC, our core expertise lies in the tailored production of viral vectors, including adeno-associated virus (AAV), lentivirus, and adenovirus. Our state-of-the-art facilities are equipped for scalable manufacturing, ensuring high-quality viral vector production to meet both research and therapeutic needs. Our expert team specializes in process development, leveraging innovative technology and extensive industry knowledge to provide clients with tailored solutions that exceed expectations. GMVC will be the ideal partner for scientists and healthcare professionals seeking reliable and efficient viral vector production services.